{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:34:17Z","timestamp":1792805657835,"version":"4.5.0"},"reference-count":190,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Cancer Society","award":["705189"],"award-info":[{"award-number":["705189"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Oncogenic kinases contribute to immunosuppression and modulate the tumor microenvironment in solid tumors. Increasing evidence supports the fundamental role of oncogenic kinase signaling networks in coordinating immunosuppressive tumor microenvironments. This has led to numerous studies examining the efficacy of kinase inhibitors in inducing anti-tumor immune responses by increasing tumor immunogenicity. Kinase inhibitors are the second most common FDA-approved group of drugs that are deployed for cancer treatment. With few exceptions, they inevitably lead to intrinsic and\/or acquired resistance, particularly in patients with metastatic disease when used as a monotherapy. On the other hand, cancer immunotherapies, including immune checkpoint inhibitors, have revolutionized cancer treatment for malignancies such as melanoma and lung cancer. However, key hurdles remain to successfully incorporate such therapies in the treatment of other solid cancers. Here, we review the recent literature on oncogenic kinases that regulate tumor immunogenicity, immune suppression, and anti-tumor immunity. Furthermore, we discuss current efforts in clinical trials that combine kinase inhibitors and immune checkpoint inhibitors to treat breast cancer and other solid tumors.<\/jats:p>","DOI":"10.3390\/ijms22052608","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T05:03:15Z","timestamp":1614920595000},"page":"2608","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9788-4401","authenticated-orcid":false,"given":"Ryuhjin","family":"Ahn","sequence":"first","affiliation":[{"name":"Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Ursini-Siegel","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, McGill University, Montr\u00e9al, QC H3G 1Y6, Canada"},{"name":"Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, QC H3T 1E2, Canada"},{"name":"Department of Experimental Medicine, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"},{"name":"Department of Oncology, McGill University, 546 Pine Avenue West, Montr\u00e9al, QC H2W 1S6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN [Gamma] and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer Immunoediting: From Immunosurveillance to Tumor Escape","volume":"3","author":"Allen","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The Immunobiology of Cancer Immunosurveillance and Immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-14-0153","article-title":"The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy","volume":"2","author":"Kim","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity","volume":"29","author":"DeNardo","year":"2010","journal-title":"Cancer Metastasis Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer Despite Immunosurveillance: Immunoselection and Immunosub-version","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and Granzymes: Function, Dysfunction and Human Pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"Nk Cell-Mediated Anti-Body-Dependent Cellular Cytotoxicity in Cancer Immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","article-title":"The Emerging Role of B Cells in Tumor Immunity","volume":"76","author":"Tsou","year":"2016","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","article-title":"The prognostic significance of B lymphocytes in invasive carcinoma of the breast","volume":"132","author":"Mahmoud","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-18-1481","article-title":"Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer","volume":"24","author":"Wouters","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12967-015-0680-0","article-title":"Analysis of in Vitro Adcc and Clinical Response to Trastuzumab: Possible Relevance of Fcgammariiia\/Fcgammariia Gene Polymorphisms and Her-2 Expression Levels on Breast Cancer Cell Lines","volume":"13","author":"Boero","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lucarini, V., Melaiu, O., Tempora, P., D\u2019Amico, S., Locatelli, F., and Fruci, D. (2021). Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. Cancers, 13.","DOI":"10.3390\/cancers13030433"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2217\/imt.10.99","article-title":"Small-Molecule Protein Kinase Inhibitors and Their Effects on the Immune System: Implications for Cancer Treatment","volume":"3","author":"Ott","year":"2011","journal-title":"Immunotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.3944","article-title":"Natural and therapy-induced immunosurveillance in breast cancer","volume":"21","author":"Kroemer","year":"2015","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","first-page":"29","article-title":"Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents","volume":"6","author":"Krueger","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors: A Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_20","first-page":"23181","article-title":"Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images","volume":"23","author":"Joel","year":"2018","journal-title":"Cell Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1073\/pnas.1817652116","article-title":"Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer","volume":"116","author":"Li","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","first-page":"1","article-title":"Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer","volume":"19","author":"Mairinger","year":"2019","journal-title":"BMC Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jnci\/djx137","article-title":"Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer","volume":"110","author":"Heindl","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/modpathol.2015.37","article-title":"Beyond immune density: Critical role of spatial heterogeneity in estrogen receptor-negative breast cancer","volume":"28","author":"Nawaz","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.cell.2018.03.073","article-title":"Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer","volume":"173","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-18-2013","article-title":"Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non\u2013Small Cell Lung Cancer","volume":"25","author":"Corredor","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.blre.2015.11.003","article-title":"Immune checkpoint blockade: Releasing the brake towards hematological malignancies","volume":"30","author":"Xia","year":"2016","journal-title":"Blood Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/0008-5472.CAN-19-1108","article-title":"CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers","volume":"80","author":"Kong","year":"2019","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1503\/cmaj.191231","article-title":"Immune checkpoint inhibitors in cancer immunotherapy","volume":"192","author":"Himmel","year":"2020","journal-title":"Can. Med. Assoc. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Yizhak","year":"2018","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with Chemotherapy in the Era of Immune Checkpoint Inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1178223418774802","article-title":"Breast Cancer Immunotherapy: An Update","volume":"12","author":"Makhoul","year":"2018","journal-title":"Breast Cancer Basic Clin. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast Cancer Immunotherapy: Facts and Hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Thompson","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase Iii Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Com-paring the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: Big 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: From TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_43","first-page":"2108","article-title":"Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study","volume":"379","author":"Emens","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (Key-note-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1490854","DOI":"10.1080\/2162402X.2018.1490854","article-title":"Tumor Mutational Burden is a Determinant of Immune-Mediated Survival in Breast Cancer","volume":"7","author":"Thomas","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zou, Y., Zou, X., Zheng, S., Tang, H., Zhang, L., Liu, P., and Xie, X. (2020). Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: A systematic review and meta-analysis. Ther. Adv. Med. Oncol., 12.","DOI":"10.1177\/1758835920940928"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for Meta-static or Locally Advanced Previously Treated Solid Tumours (Javelin Solid Tumor): A Phase 1a, Multicohort, Dose-Escalation Trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1538-7445.AM2017-2986","article-title":"Abstract 2986: Atezolizumab in Metastatic Tnbc (Mtnbc): Long-Term Clinical Outcomes and Biomarker Analyses","volume":"77","author":"Schmid","year":"2017","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: Wounds That Do Not Heal","volume":"315","author":"Flier","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1084\/jem.190.10.1375","article-title":"A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity","volume":"190","author":"Hudson","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.190.10.1367","article-title":"At the Crossroads of Inflammation and Tumorigenesis","volume":"190","author":"Prives","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)00139-2","article-title":"Mmp-9 Supplied by Bone Mar-row-Derived Cells Contributes to Skin Carcinogenesis","volume":"103","author":"Coussens","year":"2000","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1101\/gad.13.11.1382","article-title":"Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis","volume":"13","author":"Coussens","year":"1999","journal-title":"Genes Dev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","article-title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis","volume":"6","author":"Sparmann","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The Braf-Mapk Signaling Pathway is Essential for Cancer-Immune Evasion in Human Melanoma Cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/172460088800300401","article-title":"Molecular profile, tissue distribution and prognostic evaluation of a human melanoma-carcinoma antigen recognized by the murine monoclonal antibody B1.1","volume":"3","author":"Natali","year":"1988","journal-title":"Int. J. Biol. Mark."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell\u2013Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"Cdk4\/6 Inhibition Triggers Anti-Tumour Immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fimmu.2020.594775","article-title":"Tumor Cell-Secreted ISG15 Promotes Tumor Cell Migration and Immune Suppression by Inducing the Macrophage M2-Like Phenotype","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell Signaling by Receptor Tyrosine Kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0797-x","article-title":"Receptor tyrosine kinases (RTKs) in breast cancer: Signaling, therapeutic implications and challenges","volume":"17","author":"Butti","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-019-1022-2","article-title":"Targeting Tyro3, Axl and Mertk (Tam Receptors): Implications for Macrophages in the Tumor Microenvironment","volume":"18","author":"Myers","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.2174\/1573394715666190618121649","article-title":"Small-Molecule CSF1R Inhibitors as Anticancer Agents","volume":"27","author":"Xun","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/imt.15.126","article-title":"Rationally Combining Anti-Vegf Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma","volume":"8","author":"Hato","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1101\/sqb.2016.81.031377","article-title":"RON Signaling is a Key Mediator of Tumor Progression in Many Human Cancers","volume":"81","author":"Faham","year":"2016","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"63901","DOI":"10.18632\/oncotarget.19194","article-title":"EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release","volume":"8","author":"Suh","year":"2017","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41388-020-1182-y","article-title":"Egfr E746-A750 Deletion in Lung Cancer Represses Anti-Tumor Immunity through the Exosome-Mediated Inhibition of Dendritic Cells","volume":"39","author":"Yu","year":"2020","journal-title":"Oncogene"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/0008-5472.CAN-17-1973","article-title":"Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer","volume":"78","author":"Ludwig","year":"2018","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1074\/jbc.272.14.9581","article-title":"Functional Importance of Shc Tyrosine 317 on Insulin Signaling in Rat1 Fibroblasts Expressing Insulin Receptors","volume":"272","author":"Ishihara","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1507\/endocrj.47.373","article-title":"The Functional Significance of Shc in Insulin Signaling as a Substrate of the Insulin Receptor","volume":"47","author":"Sasaoka","year":"2000","journal-title":"Endocr. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCRESAHA.109.206326","article-title":"Endothelial Cell Adhesion to the Extracellular Matrix Induces c-Src\u2013Dependent VEGFR-3 Phosphorylation Without the Activation of the Receptor Intrinsic Kinase Activity","volume":"106","author":"Galvagni","year":"2010","journal-title":"Circ. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8461","DOI":"10.1128\/MCB.01491-06","article-title":"Screening for PTB Domain Binding Partners and LigandSpecificity Using Proteome-Derived NPXY Peptide Arrays","volume":"26","author":"Smith","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Foster, B.M., Zaidi, D., Young, T.R., Mobley, M.E., and Kerr, B.A. (2018). CD117\/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines, 6.","DOI":"10.1101\/256099"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/jcb.25561","article-title":"The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness","volume":"117","author":"Ha","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"15951","DOI":"10.1074\/jbc.C113.527523","article-title":"Adapter Protein Shc Regulates Janus Kinase 3 Phosphorylation","volume":"289","author":"Mishra","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"23337","DOI":"10.1074\/jbc.270.40.23337","article-title":"Shc and a Novel 89-kDa Component Couple to the Grb2-Sos Complex in Fibroblast Growth Factor-2-stimulated Cells","volume":"270","author":"Klint","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.4161\/cc.7.13.6205","article-title":"The ShcA Adaptor Protein is a Critical Regulator of Breast Cancer Progression","volume":"7","author":"Muller","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/0008-5472.CAN-10-2229","article-title":"Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response","volume":"70","author":"Cory","year":"2010","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ahn, R., Sabourin, V., Bolt, A.M., H\u00e9bert, S., Totten, S., De Jay, N., Festa, M.C., Young, Y.K., Im, Y.K., and Pawson, T. (2017). The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat. Commun., 8.","DOI":"10.1038\/ncomms14638"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e1376155","DOI":"10.1080\/2162402X.2017.1376155","article-title":"Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer","volume":"7","author":"Kumar","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Kumagai, S., Koyama, S., and Nishikawa, H. (2021). Antitumour immunity regulated by aberrant ERBB family signalling. Nat. Rev. Cancer, 1\u201317.","DOI":"10.1038\/s41568-020-00322-0"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","article-title":"Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells","volume":"69","author":"Xin","year":"2009","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/2159-8290.CD-12-0480","article-title":"Inhibition of Ron Kinase Blocks Conversion of Micrometastases to Overt Metastases by Boosting Antitumor Immunity","volume":"3","author":"Eyob","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.201242505","article-title":"Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response","volume":"43","author":"Tymoszuk","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7150\/ijbs.22955","article-title":"Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes","volume":"14","author":"Yang","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/j.cllc.2018.12.022","article-title":"Afatinib with Pembrolizumab for Treatment of Patients with Locally Advanced\/Metastatic Squamous Cell Carcinoma of the Lung: The Lux-Lung Io\/Keynote 497 Study Protocol","volume":"20","author":"Levy","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","article-title":"Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma","volume":"70","author":"Atkins","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"viii208","DOI":"10.1093\/annonc\/mdy282.006","article-title":"622pd-Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (Hcc) and Elevated Alpha-Fetoprotein (Afp) Following First-Line Sorafenib: Patient Reported Outcome Results across Two Phase Iii Studies (Reach-2 and Reach)","volume":"29","author":"Zhu","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212577","article-title":"Second-line treatment options in hepatocellular carcinoma","volume":"8","author":"Marino","year":"2019","journal-title":"Drugs Context"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Ma, B., Rudin, C., Cervantes, A., Dowlati, A., Costa, D., Schmid, P., Heist, R., Villaflor, V., Sarkar, I., and Huseni, M. (2016). 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Ann. Oncol., 27.","DOI":"10.1016\/S0923-7534(21)00599-8"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S1556-0864(16)30246-5","article-title":"136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial","volume":"11","author":"Ahn","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.4078","article-title":"The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death","volume":"22","author":"Pozzi","year":"2016","journal-title":"Nat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3389\/fimmu.2017.01544","article-title":"Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy","volume":"8","author":"Muntasell","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_105","first-page":"69","article-title":"Jak2 Inhibition Prevents Nk-Released Ifn\u03b3-Mediated Pd-L1 Upreg-ulation and Enhances Cetuximab Mediated Adcc of Hnc Cells (Tum2p.1014)","volume":"194","author":"Ferris","year":"2015","journal-title":"J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/2326-6066.CIR-18-0193","article-title":"A High-Throughput Immune-Oncology Screen Identifies Egfr Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-Lymphocyte Tumor Cell Killing","volume":"6","author":"Lizotte","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.2147\/OTT.S178497","article-title":"Immunotherapy combined with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer treatment","volume":"11","author":"Liang","year":"2018","journal-title":"Oncol. Targets Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"54137","DOI":"10.18632\/oncotarget.11021","article-title":"Egfr-Targeted Therapy Results in Dramatic Early Lung Tumor Regression Accompanied by Imaging Response and Immune Infiltration in Egfr Mutant Transgenic Mouse Models","volume":"7","author":"Venugopalan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/ijc.32191","article-title":"EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies","volume":"145","author":"Jia","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in Neomonarch, Phase Ii Neoadjuvant Study in Hr+\/Her2\u2212 Breast Cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","article-title":"The Cdk4\/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of Pd-L1 Checkpoint Blockade","volume":"22","author":"Schaer","year":"2018","journal-title":"Cell Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.1158\/1078-0432.CCR-18-1256","article-title":"Abemaciclib is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling","volume":"24","author":"Dowless","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_114","first-page":"91","article-title":"Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","article-title":"Atezolizumab Plus Cobimetinib and Vemurafenib in Braf-Mutated Melanoma Patients","volume":"25","author":"Sullivan","year":"2019","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","article-title":"Combined PD-1, BRAF and MEK Inhibition in Advanced Braf-Mutant Melanoma: Safety Run-in and Biomarker Cohorts of COMBI-I","volume":"26","author":"Dummer","year":"2020","journal-title":"Nat. Med."},{"key":"ref_118","first-page":"279ra41","article-title":"Improved Antitumor Activity of Immunotherapy with Braf and Mek Inhibitors in Braf (V600e) Melanoma","volume":"7","author":"Mok","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The Braf and Mek Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immuno-modulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e1335843","DOI":"10.1080\/2162402X.2017.1335843","article-title":"Mek Inhibition and Immune Responses in Advanced Melanoma","volume":"6","author":"Reinhard","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"Braf Inhibition is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e1238557","DOI":"10.1080\/2162402X.2016.1238557","article-title":"Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma","volume":"5","author":"Deken","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1158\/0008-5472.CAN-17-0393","article-title":"Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis","volume":"77","author":"Young","year":"2017","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.tcb.2016.06.005","article-title":"Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer","volume":"26","author":"Chu","year":"2016","journal-title":"Trends Cell Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"Pi3k-Akt-mTOR Inhibition in Cancer Immunotherapy, Re-dux","volume":"48","author":"Massi","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of Pd-L1 Expression by Oncogenic Activation of the Akt-mTOR Pathway in Non-Small Cell Lung Cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni.3311","article-title":"The tumor suppressor PTEN has a critical role in antiviral innate immunity","volume":"17","author":"Li","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ncb3379","article-title":"Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation","volume":"18","author":"Welte","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.celrep.2018.02.049","article-title":"Pi3k\/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation","volume":"22","author":"Villegas","year":"2018","journal-title":"Cell Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","article-title":"Translation control of the immune checkpoint in cancer and its therapeutic targeting","volume":"25","author":"Xu","year":"2019","journal-title":"Nat. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41591-018-0217-1","article-title":"Translational Control of Tumor Immune Escape Via the Eif4f-Stat1-Pd-L1 Axis in Mela-noma","volume":"24","author":"Cerezo","year":"2018","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/0008-5472.CAN-11-0307","article-title":"Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN-\u03b3+IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors","volume":"72","author":"Marshall","year":"2012","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Prabhu, S.A., Moussa, O., Miller, W.H., and Del Rinc\u00f3n, S.V. (2020). The Mnk1\/2-Eif4e Axis as a Potential Therapeutic Target in Melanoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114055"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","article-title":"TBCRC 032 IB\/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer","volume":"26","author":"Lehmann","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1535-7163.MCT-18-1206","article-title":"SF2523: Dual PI3K\/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer","volume":"18","author":"Joshi","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-16-2142","article-title":"PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses","volume":"23","author":"Sai","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/bjc.2011.15","article-title":"Temsirolimus, an mTOR Inhibitor, Enhances An-ti-Tumour Effects of Heat Shock Protein Cancer Vaccines","volume":"104","author":"Wang","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2013.03.040","article-title":"Phase 2 Trial of Single-Agent Everolimus in Chemotherapy-Naive Patients with Castration-Resistant Prostate Cancer (Sakk 08\/08)","volume":"64","author":"Templeton","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fimmu.2019.00556","article-title":"Small-Molecule Immunosuppressive Drugs and Therapeutic Immu-noglobulins Differentially Inhibit Nk Cell Effector Functions in Vitro","volume":"10","author":"Amandine","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Liu, J., Liu, D., Li, J., Zhu, L., Zhang, C., Lei, K., Xu, Q., and You, R. (2017). Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170246"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00262-018-2288-8","article-title":"The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: Results from a phase I clinical trial","volume":"68","author":"Huijts","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1479-5876-10-28","article-title":"Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition","volume":"10","author":"Hamilton","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1158\/2326-6066.CIR-14-0058","article-title":"A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF\u2013Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer","volume":"2","author":"Chen","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-014-0294-y","article-title":"Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine","volume":"12","author":"Kwilas","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e22890","DOI":"10.4161\/onci.22890","article-title":"Vemurafenib Enhances Mhc Induction in Braf (V600e) Homozygous Melanoma Cells","volume":"2","author":"Sapkota","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/2326-6066.CIR-16-0177","article-title":"Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells","volume":"4","author":"Brea","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1038\/s41467-020-16588-9","article-title":"Multiplexed Relative and Absolute Quantitative Immunopeptidomics Reveals Mhc I Repertoire Alterations Induced by Cdk4\/6 Inhibition","volume":"11","author":"Stopfer","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/sj.leu.2404787","article-title":"Identification of T-cell epitopes for cancer immunotherapy","volume":"21","author":"Kessler","year":"2007","journal-title":"Leukemia"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The Molecular Regulation of Janus Kinase (Jak) Activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT Pathway at Twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"14111","DOI":"10.1074\/jbc.M511797200","article-title":"Role of Stat3 in Type I Interferon Responses. Negative Regulation of Stat1-Dependent Inflammatory Gene Activation","volume":"281","author":"Ho","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between Cancer and Immune Cells: Role of Stat3 in the Tumour Microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cyto.2015.11.011","article-title":"The good and the bad faces of STAT1 in solid tumours","volume":"89","author":"Meissl","year":"2017","journal-title":"Cytokine"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1084\/jem.20150712","article-title":"Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide","volume":"213","author":"Madera","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.3389\/fimmu.2020.02189","article-title":"STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity","volume":"11","author":"Meissl","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-08743-8","article-title":"STAT1 signaling shields T cells from NK cell-mediated cytotoxicity","volume":"10","author":"Kang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0092-1157(88)90026-1","article-title":"The preparation of cultured rabies virus and the production of antiserum for human use","volume":"16","author":"Consales","year":"1988","journal-title":"J. Biol. Stand."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1073\/pnas.1818210116","article-title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","volume":"116","author":"Miranda","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e20191340","DOI":"10.1084\/jem.20191340","article-title":"Glioma Stem-Like Cells Evade Interferon Suppression through Mbd3\/Nurd Complex-Mediated Stat1 Downregulation","volume":"4","author":"Zhan","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"De Angelis, C., Fu, X., Cataldo, M.L., Nardone, A., Pereira, R., Veeraraghavan, J., Nanda, S., Qin, L., Sethunath, V., and Wang, T. (2021). Activation of the IFN Signaling Pathway is Associated with Resistance to Cdk4\/6 Inhibitors and Immune Checkpoint Activation in Er-Positive Breast Cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-19-4191"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Huang, J., Chen, P., Liu, K., Liu, J., Zhou, B., Wu, R., Peng, Q., Liu, Z.X., Li, C., and Kroemer, G. (2020). Cdk1\/2\/5 Inhibition Overcomes Ifng-Mediated Adaptive Immune Resistance in Pancreatic Cancer. Gut.","DOI":"10.1136\/gutjnl-2019-320441"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Showalter, L.E., Oechsle, C., Ghimirey, N., Steele, C., Czerniecki, B.J., and Koski, G.K. (2019). Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210209"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab Upregulates Pd-L1 as a Potential Mechanism of Trastuzumab Resistance through Engagement of Immune Effector Cells and Stimulation of Ifn\u03b3 Secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0800-6","article-title":"Targeting tumour microenvironment by tyrosine kinase inhibitor","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/mol.110.070862","article-title":"Off-Target Serine\/Threonine Kinase 10 Inhibition by Erlotinib Enhances Lymphocytic Activity Leading to Severe Skin Disorders","volume":"80","author":"Yamamoto","year":"2011","journal-title":"Mol. Pharm. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.1061663","article-title":"Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family","volume":"293","author":"Lu","year":"2001","journal-title":"Science"},{"key":"ref_176","first-page":"508","article-title":"The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells","volume":"507","author":"Paolino","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/bjc.2016.428","article-title":"Giving AXL the axe: Targeting AXL in human malignancy","volume":"116","author":"Gay","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The Tam Family: Phosphatidylserine-Sensing Receptor Tyrosine Kinases Gone Awry in Cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_179","first-page":"1","article-title":"TAM receptors, Phosphatidylserine, inflammation, and Cancer","volume":"17","author":"Maimon","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor Tyrosine Kinases and Tlr\/Il1rs Unexpectedly Activate Myeloid Cell Pi3k\u03b3, a Single Convergent Point Promoting Tumor Inflammation and Progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"27556","DOI":"10.1073\/pnas.1920377117","article-title":"MNK2 governs the macrophage antiinflammatory phenotype","volume":"117","author":"Bartish","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Liu, G., Jin, Z., and Lu, X. (2020). Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib. Int. J. Mol. Sci., 21.","DOI":"10.26226\/morressier.5f69edb69b74b699bf38c684"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1017\/cts.2018.127","article-title":"2025 Targeting immunosuppressive myeloid cells to enhance cancer immunotherapy","volume":"2","author":"Lu","year":"2018","journal-title":"J. Clin. Transl. Sci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e103790","DOI":"10.15252\/embj.2019103790","article-title":"Microglia Promote Glioblastoma Via mTOR-Mediated Immunosuppression of the Tumour Microenvironment","volume":"39","author":"Dumas","year":"2020","journal-title":"EMBO J."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41467-018-04392-5","article-title":"mTOR Coordinates Transcriptional Programs and Mitochondrial Metabolism of Activated T (Reg) Subsets to Protect Tissue Homeo-stasis","volume":"9","author":"Chapman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Shi, L., Chen, X., Zang, A., Li, T., Hu, Y., Ma, S., L\u00fc, M., Yin, H., Wang, H., and Zhang, X. (2019). TSC1\/mTOR-controlled metabolic\u2013epigenetic crosstalk underpins DC control of CD8+ T-cell homeostasis. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.3000420"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2017.12.008","article-title":"Checkpoint inhibitors in breast cancer\u2014Current status","volume":"63","author":"Polk","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07277-9","article-title":"Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Katholnig, K., Sch\u00fctz, B., Fritsch, S.D., Sch\u00f6rghofer, D., Linke, M., Sukhbaatar, N., Matschinger, J.M., Unterleuthner, D., Hirtl, M., and Lang, M. (2019). Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis. JCI Insight, 4.","DOI":"10.1172\/jci.insight.124164"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2608\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:33:15Z","timestamp":1760160795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":190,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22052608"],"URL":"https:\/\/doi.org\/10.3390\/ijms22052608","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}